Eli Lilly and (LLY) Receives Daily Coverage Optimism Rating of 0.15
Media coverage about Eli Lilly and (NYSE:LLY) has trended somewhat positive recently, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eli Lilly and earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.0504371398136 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s analysis:
- Eli Lilly (LLY) a Hold on Anemic Earnings Momentum (investorplace.com)
- FY2017 EPS Estimates for Eli Lilly and Company (LLY) Cut by Analyst (americanbankingnews.com)
- Report: Former Eli Lilly exec Azar considered front-runner for HHS spot (massdevice.com)
- EuroBiotech Report—Lilly, CureVac in $1.8B deal, Brexit hits AstraZeneca’s hiring, uniQure’s gamble, savolitinib and InflaRx (fiercebiotech.com)
- Ken Langone on Black Monday Crash, Regulatory Landscape (finance.yahoo.com)
Shares of Eli Lilly and (LLY) opened at 87.23 on Friday. The company has a market cap of $92.03 billion, a P/E ratio of 37.75 and a beta of 0.34. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $89.09. The stock’s 50 day moving average price is $84.38 and its 200-day moving average price is $82.29.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the prior year, the company earned $0.86 EPS. Eli Lilly and’s revenue was up 7.8% compared to the same quarter last year. Equities analysts expect that Eli Lilly and will post $4.16 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.38%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is 90.04%.
Several equities analysts recently commented on LLY shares. UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 target price for the company. in a research report on Wednesday, July 26th. BMO Capital Markets restated a “sell” rating and set a $71.00 target price on shares of Eli Lilly and in a research report on Thursday, September 28th. Morgan Stanley set a $86.00 target price on Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Piper Jaffray Companies restated a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a research report on Friday, October 13th. Finally, Berenberg Bank restated a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research report on Friday, August 4th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly and has an average rating of “Hold” and a consensus price target of $88.97.
In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the transaction, the insider now directly owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 990,000 shares of company stock valued at $82,949,650 over the last quarter. 0.20% of the stock is owned by corporate insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.